UT Southwestern registers RIPCORD trial testing PSMA PET-guided radiotherapy in prostate cancer

This week's item concerns a single newly registered trial with Telix Pharmaceuticals listed as a collaborator rather than the sponsor.

• The study, known by the acronym RIPCORD (NCT07674771), is sponsored by University of Texas Southwestern Medical Center, with Varian, a Siemens Healthineers Company, and Telix Pharmaceuticals (Innovations) Pty Ltd as collaborators. It is not yet recruiting, with an estimated start of October 2026 and estimated primary completion of June 15, 2029.¹ The trial aims to measure the reduction in PSMA-avid tumor volume and radiotherapy treatment intensity achieved through PET-guided, response-adapted stereotactic ablative radiotherapy in patients with poly-metastatic, castration-sensitive prostate cancer.¹ It is designed as an early Phase 1, single-arm study with an estimated enrollment of 30 participants.¹ Patients will receive baseline PSMA PET imaging to identify poly-metastatic hormone-sensitive prostate cancer, followed by standard systemic therapy including ADT and androgen receptor signaling inhibitors for up to three months before protocol radiotherapy.¹